Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022
April 06, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase,...
Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
March 21, 2022 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2022 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Prices Upsized $275 Million Convertible Senior Notes Offering
March 08, 2022 21:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $275 million aggregate principal amount of 2.25%...
Travere Announces Proposed Convertible Senior Notes Offering
March 08, 2022 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $250 million aggregate...
Travere Therapeutics to Present at the Barclays Global Healthcare Conference
March 03, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the Barclays Global Healthcare Conference on...
Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease
February 28, 2022 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases...
Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 16:01 ET
|
Travere Therapeutics, Inc.
NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 14, 2022 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results
February 10, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2021 financial results on Thursday, February 24,...